C. diff Risk


Oral Bioavailability



4-6 mg/kg IV q24h

30+ mL/min0 - 30 mL/min4-6 mg/kg IV q24h4-6 mg/kg IV q48h

4-6 mg/kg IV qHD

Consider increasing dose by 50% after dialysis on 72 hr intradialytic day.

4-6 mg/kg IV q24h

4-6 mg/kg IV q48h

General Information

Additional Information

Infectious Disease consultation recommended.

Inactivated by pulmonary surfactant and therefore insufficient for pulmonary infection.

Adverse Effects

Myopathy including rhabdomyolysis, GI side effects common, rash, phlebitis, increased INR.

Common Usage

Targeted therapy of resistant gram positive infections with MRSA (particularly when MIC>=2) and VRE including endovascular infection.

Drug Monitoring

Creatine kinase weekly.

Major Interactions

Statins and fibrates: monitor creatine kinase or hold while on daptomycin therapy (increased myopathy).


Antimicrobial class: Cyclic lipopeptide, depolarizes bacterial cell membrane

Pregnancy category: B